Menotropyn | Menovazine bottles, 40 ml of p21fro60 lyophrof. r-ra d / in 75 ME + solvent vials of 10 pieces.
Special Price
$268.69
Regular Price
$284.00
In stock
SKU
BID463468
Latin name
Menopur
Menopur
Latin name
Menopur
Release form
Lyophilisate for preparation for injection for injection
Packing
10 pcs
Pharmacological action
MENOPUR is a drug of human menopausal gonadotropin (hMG), a high degree of purification. It belongs to the group of menorotopins, contains FSH and LH in a ratio of 1: 1. The drug is obtained from the urine of postmenopausal women.
In women, the drug causes an increase in estrogen levels in the blood and stimulates the growth and maturation of ovarian follicles, proliferation of the endometrium.
In men, the use of Menopur leads to an increase in the concentration of testosterone in the blood and stimulates spermatogenesis by acting on the Sertoli cells of the seminiferous tubules.
Pharmacokinetics
Absorption. Cmax FSH in plasma is reached within 7 hours after sc or intramuscular administration.
distribution. Vd after repeated doses of 150 IU for 7 days is 8.9 ± 3.5 IU / l for p / quad and 8.5 ± 3.2 IU / l for i / m administration.
Metabolism. Not studied.
Withdrawal. The concentration of FSH in the blood decreases gradually. T1 / 2 is (30 ± 11) hours for s / c and (27 ± 9) hours for intramuscular administration. It is excreted mainly by the kidneys.
Indications
For women
infertility due to hypothalamic-pituitary disorders (to stimulate the growth of one dominant follicle)
during assisted reproductive techniques for the onset of conception (stimulation of the growth of multiple follicles).
For men
stimulation of spermatogenesis with azoospermia or oligoasthenospermia, due to primary or secondary hypogonadotropic hypogonadism (in combination with therapy with drugs of human chorionic gonadotropin, for example, the drug Horagon).
Contraindications
persistent ovarian enlargement, ovarian cyst (not caused by polycystic ovary syndrome)
genital malformations, uterine fibroids, incompatible
pregnancy, metrorrhagia, and other bleeding of unclear etiology of breast cancer srdlkrd , testicular tumor
high FSH concentration in primary ovarian failure
pregnancy and lactation period
tumors of the hypothalamic-pituitary region
androgen-dependent e
tumors hypersensitivity to the drug or its components.
If you have one of these diseases, you should always consult your doctor before taking the drug.
Caution: see "Special instructions."
Use during pregnancy and lactation
MenopurВ® is contraindicated in pregnancy and lactation.
During pregnancy, the manifestations of ovarian hyperstimulation syndrome are exacerbated, their duration is increased, this condition can lead to a threat to the patient’s life.
Dosage and administration
The drug is administered in / m or s / c. An injection is prepared immediately prior to administration using the supplied solvent.
Unless otherwise prescribed, the following treatment regimen is recommended:
For women
In infertility, due to hypothalamic-pituitary impairment, in order to stimulate the growth of one dominant
follicle, the dosage regimen of the drug is set individually. The optimal dose and duration of treatment are selected on the basis of ultrasound of the ovaries, determination of estrogen levels in the blood, as well as clinical observation. Follicle maturation is judged by an increase in the level of estrogen in the blood.
The initial dose of Menopur® is 75-150 IU (1-2 bottles / day). In the absence of an ovarian reaction, the dose is gradually increased until the level of estrogen in the blood increases or follicles grow. The dose is left unchanged until the moment when the concentration of estrogen reaches the preovulatory level. With a rapid rise in estrogen levels at the beginning of stimulation, the dose should be reduced.
In order to induce ovulation, 1-200 after the last injection of Menopur, 5,000-10,000 IU of hCG are administered once.
For men: in order to stimulate spermatogenesis, 1,000-3,000 IU of hCG is administered 3 times a week until the level of testosterone in the blood normalizes. Then, for several months, Menopur® is administered 3 times a week at 75-150 IU (1-2 bottles).
Side effects of
From the genitourinary system: ovarian hyperstimulation syndrome (OHS), pain in the lower abdomen.
From the nervous system: headache.
From the digestive system: abdominal pain, nausea, flatulence.
General reactions and reactions at the injection site: pain, swelling and irritation at the injection site.
Gynecomastia may occur in men.
The most serious side effect is OHSS and its associated complications: thromboembolic syndrome and ovarian twisting. If any of the side effects specified in the instructions are aggravated, or any other side effects not listed in the instructions develop, you should inform your doctor.
Drug Interactions
Menopour® can be used in combination with Horagon (human chorionic gonadotropin) in women - to induce ovulation, after stimulation of follicle growth in men - to stimulate spermatogenesis.
overdose
Symptoms: cases of overdose are unknown, however, in such situations, the development of CSF and thromboembolic complications should be expected.
Symptoms of CSF - ovarian enlargement, abdominal pain, nausea, vomiting, diarrhea, weight gain, oliguria, ascites, hydrothorax, hemoperitoneum, hemoconcentration, shortness of breath
Treatment: usually do not require additional treatment and are self-administered3. See the Special Instructions section for details.
Storage conditions
The drug should be stored out of the reach of children, protected from light at a temperature not exceeding 25 РC.
Expiration
2 Year
Deystvuyuschee substances
Menotropyn
dosage form
dosage form
injection
Ferring GmbH, Germany
Menopur
Release form
Lyophilisate for preparation for injection for injection
Packing
10 pcs
Pharmacological action
MENOPUR is a drug of human menopausal gonadotropin (hMG), a high degree of purification. It belongs to the group of menorotopins, contains FSH and LH in a ratio of 1: 1. The drug is obtained from the urine of postmenopausal women.
In women, the drug causes an increase in estrogen levels in the blood and stimulates the growth and maturation of ovarian follicles, proliferation of the endometrium.
In men, the use of Menopur leads to an increase in the concentration of testosterone in the blood and stimulates spermatogenesis by acting on the Sertoli cells of the seminiferous tubules.
Pharmacokinetics
Absorption. Cmax FSH in plasma is reached within 7 hours after sc or intramuscular administration.
distribution. Vd after repeated doses of 150 IU for 7 days is 8.9 ± 3.5 IU / l for p / quad and 8.5 ± 3.2 IU / l for i / m administration.
Metabolism. Not studied.
Withdrawal. The concentration of FSH in the blood decreases gradually. T1 / 2 is (30 ± 11) hours for s / c and (27 ± 9) hours for intramuscular administration. It is excreted mainly by the kidneys.
Indications
For women
infertility due to hypothalamic-pituitary disorders (to stimulate the growth of one dominant follicle)
during assisted reproductive techniques for the onset of conception (stimulation of the growth of multiple follicles).
For men
stimulation of spermatogenesis with azoospermia or oligoasthenospermia, due to primary or secondary hypogonadotropic hypogonadism (in combination with therapy with drugs of human chorionic gonadotropin, for example, the drug Horagon).
Contraindications
persistent ovarian enlargement, ovarian cyst (not caused by polycystic ovary syndrome)
genital malformations, uterine fibroids, incompatible
pregnancy, metrorrhagia, and other bleeding of unclear etiology of breast cancer srdlkrd , testicular tumor
high FSH concentration in primary ovarian failure
pregnancy and lactation period
tumors of the hypothalamic-pituitary region
androgen-dependent e
tumors hypersensitivity to the drug or its components.
If you have one of these diseases, you should always consult your doctor before taking the drug.
Caution: see "Special instructions."
Use during pregnancy and lactation
MenopurВ® is contraindicated in pregnancy and lactation.
During pregnancy, the manifestations of ovarian hyperstimulation syndrome are exacerbated, their duration is increased, this condition can lead to a threat to the patient’s life.
Dosage and administration
The drug is administered in / m or s / c. An injection is prepared immediately prior to administration using the supplied solvent.
Unless otherwise prescribed, the following treatment regimen is recommended:
For women
In infertility, due to hypothalamic-pituitary impairment, in order to stimulate the growth of one dominant
follicle, the dosage regimen of the drug is set individually. The optimal dose and duration of treatment are selected on the basis of ultrasound of the ovaries, determination of estrogen levels in the blood, as well as clinical observation. Follicle maturation is judged by an increase in the level of estrogen in the blood.
The initial dose of Menopur® is 75-150 IU (1-2 bottles / day). In the absence of an ovarian reaction, the dose is gradually increased until the level of estrogen in the blood increases or follicles grow. The dose is left unchanged until the moment when the concentration of estrogen reaches the preovulatory level. With a rapid rise in estrogen levels at the beginning of stimulation, the dose should be reduced.
In order to induce ovulation, 1-200 after the last injection of Menopur, 5,000-10,000 IU of hCG are administered once.
For men: in order to stimulate spermatogenesis, 1,000-3,000 IU of hCG is administered 3 times a week until the level of testosterone in the blood normalizes. Then, for several months, Menopur® is administered 3 times a week at 75-150 IU (1-2 bottles).
Side effects of
From the genitourinary system: ovarian hyperstimulation syndrome (OHS), pain in the lower abdomen.
From the nervous system: headache.
From the digestive system: abdominal pain, nausea, flatulence.
General reactions and reactions at the injection site: pain, swelling and irritation at the injection site.
Gynecomastia may occur in men.
The most serious side effect is OHSS and its associated complications: thromboembolic syndrome and ovarian twisting. If any of the side effects specified in the instructions are aggravated, or any other side effects not listed in the instructions develop, you should inform your doctor.
Drug Interactions
Menopour® can be used in combination with Horagon (human chorionic gonadotropin) in women - to induce ovulation, after stimulation of follicle growth in men - to stimulate spermatogenesis.
overdose
Symptoms: cases of overdose are unknown, however, in such situations, the development of CSF and thromboembolic complications should be expected.
Symptoms of CSF - ovarian enlargement, abdominal pain, nausea, vomiting, diarrhea, weight gain, oliguria, ascites, hydrothorax, hemoperitoneum, hemoconcentration, shortness of breath
Treatment: usually do not require additional treatment and are self-administered3. See the Special Instructions section for details.
Storage conditions
The drug should be stored out of the reach of children, protected from light at a temperature not exceeding 25 РC.
Expiration
2 Year
Deystvuyuschee substances
Menotropyn
dosage form
dosage form
injection
Ferring GmbH, Germany
Submit your review to Earn 10 Reward Points click here to login
Write Your Own Review